Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo® in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.
"We are excited to make NovoPen Echo® available in the United States for patients and believe this pen can help patients fine tune their dosing while offering added reassurance they are managing their diabetes appropriately," said George McAvoy, vice president, NovoLog® brand team at Novo Nordisk.
Half-unit dose increments allow for finer adjustments, which can be particularly important for children. In addition, 12 fun removable skins are available for a customized look, including kid-friendly designs.
"Children with type 1 diabetes have unique needs in regards to diabetes management," said Children with Diabetes founder Jeff Hitchcock. "It is so important that new, innovative tools continue to be developed so that children and caregivers have options. NovoPen Echo®, which features half-unit dosing from the start and memory function, is a welcome addition to the tools children with diabetes and their caregivers have available, especially when kids are away from home."
This pen is the latest insulin delivery system offered from Novo Nordisk, and is available to patients for use with NovoLog® PenFill® cartridges.
Novo Nordisk has already launched NovoPen Echo® in Europe, Canada, and Israel.
Leicester to become part of global program to tackle diabetes in urban areas